Form 4: Cidara CMO's Tax-Related Stock Disposition

Cidara Therapeutics' Chief Medical Officer, Nicole Davarpanah, reported the disposition of 10,332 common shares to cover tax obligations from RSU vesting, while also acquiring 200 shares via ESPP.

Summary

• Nicole Negar Davarpanah, Chief Medical Officer of Cidara Therapeutics, Inc. (CDTX), reported a transaction involving common stock.
• On December 10, 2025, 10,332 shares of common stock were disposed of to cover tax liabilities associated with the vesting of Restricted Stock Units (RSUs).
• The deemed price for these disposed shares was $219.6 per share.
• Following this transaction, Ms. Davarpanah beneficially owns 21,286 shares of common stock directly.
• The reported beneficial ownership includes 200 shares acquired through the Issuer's Employee Stock Purchase Plan (ESPP) on November 20, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there was a disposition of shares, it was for tax purposes related to RSU vesting, which is an underlying positive compensation event. The additional acquisition of shares via ESPP further contributes to a positive view of insider equity participation.

Positives

• The underlying event of RSU vesting indicates compensation for the Chief Medical Officer, which is a positive for executive incentives.
• The acquisition of 200 shares through the Employee Stock Purchase Plan (ESPP) on November 20, 2025, demonstrates continued participation in the company's equity programs.

Negatives

• A disposition of 10,332 shares occurred, although it was for tax withholding purposes rather than a voluntary sale.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction filing (Form 4) common for executives in publicly traded companies, reflecting compensation events and associated tax obligations. It does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The impact is minimal as this is a routine insider transaction for tax purposes, not indicative of a change in management's confidence or a significant shift in ownership structure.
• Employees: The RSU vesting and ESPP participation highlight ongoing equity compensation programs for company executives and employees.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the disposition of shares for tax withholding on RSU vesting and a small acquisition via an ESPP. Such transactions are common and generally do not signal a change in management's outlook on the company's prospects or warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing provides no new material information to alter an existing investment thesis.

Keywords

Cidara Therapeutics, CDTX, Form 4, Insider Transaction, Chief Medical Officer, RSU Vesting, Stock Disposition, Tax Withholding, ESPP